


What is claimed is:


1. A method for treating sexual dysfunction, which comprises
 10 administering to an individual in need thereof a therapeutically effective amount of an active agent on an as-needed basis, wherein said active agent is selected from the group consisting of:

a. Substituted-benzyl or substituted-indolyl cyclic amino- substituted N-aryl or heteroaryl cyclic amines (illustrated below) as disclosed in U.S. Patent
 15 No. 6,225,324 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




and/or hydrates thereof wherein

20 Z is selected from phenyl, benzodioxolone, benzodioxole, benzothiazole, pyridine, pyridazine, pyrimidine, and quinoline moieties that are unsubstituted or optimally substituted with one to three substituents selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, and halo; the solid and dotted lines denote either a double or a single covalent bond; 25 m and n are independently integers 1 to 3; and





in which R₁ and R₂ are independently selected from hydrogen, halogen, and alkoxy, and R₃ is hydrogen, halogen, or cyano;

b. The compound shown below identified as BMS-296859;




10 c. Thiophene and benzothiophene compounds (illustrated below) as disclosed in U.S. Patent No. 6,262,056 and PCT Publication No. WO99/02516 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20 d. 3-[2-(1-(4'-piperonylpiperazinyl))indolyl]-carboxaldehydes (illustrated below) as disclosed in PCT Publication No. WO94/25454 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

5




10

e. 3-[4-(3-substituted phenyl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propanol derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *Pharmazie* 57: 515-8 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



15


f. 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *J Med Chem* 45: 4128-39 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



20


g. The compound shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

5




10

h. 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-2-yl)propane derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *Pharmazie* 57: 355-7 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

i. 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives (illustrated below) as disclosed in Martinez-Esparza J *et al.* (2001) *J Med Chem* 44: 418-28 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



20


j. 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propane derivatives (illustrated below) as disclosed in Martinez J *et al.* (2001) *Eur J Med Chem* 36: 55-61 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



5


k. 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives (illustrated below) as disclosed in Oficialdegui AM *et al.* (2000) *Farmaco* 55: 345-53 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof:

10




1. The compound VN2222 (illustrated below) as identified and disclosed in Tordera RM *et al.* (2002) *Eur J Pharmacol* 442: 63-71 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

15




m. Arylpiperazinyl cyclohexyl derivatives (illustrated below) as disclosed in U.S. Patent No. 6,465,482 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

20




5


n. Aryl piperazinyl cyclohexyl derivatives (illustrated below) as disclosed in U.S. Patent No. 6,337,336 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 o. Arylpiperazinyl-cyclohexyl indole derivatives (illustrated below) as disclosed in U.S. Patent No. 6,313,126 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 p. 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]-
amines (illustrated below) as disclosed in U.S. Patent No. 6,313,114 and
salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites,
and derivatives thereof;




q. N-arloxyethyl-alkylamines (illustrated below) as disclosed in U.S. Patent No. 6,291,683 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




r. Tetrahydroisoquinolinyl-indole derivatives (illustrated below) as disclosed in U.S. Patent No. 6,245,780 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 s. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,221,863 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 t. 1,4-disubstituted cyclohexane derivatives (illustrated below) as disclosed in U.S. Patent No. 6,200,994 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20 u. Indol-3-yl-cyclohexylamine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,162,803 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




v. N-aryloxyethyl-indoly-alkylamines (illustrated below) as disclosed in U.S. Patent No. 6,150,533 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



10 w. Aryloxyethyl-indoly-alkylamine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,121,307 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




x. N-aryloxyethylarginine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,110,956 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5

y. Aryl-8-azabicyclo[3.2.1]octanes (illustrated below) as disclosed in PCT Publication No. WO02/96906 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

z. Azaindole derivatives (illustrated below) as disclosed in PCT Publication No. WO00/64898 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

aa. Dihydroisoquinolinyl-indole derivatives (illustrated below) as disclosed in PCT Publication No. WO00/64886 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20

bb. 3,4-dihydro-2H-benzo [1,4] oxazine derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40581 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




cc. 3,4-dihydro-2Hbenzo [1, 4] oxazinyl-methyl)- [3- (IH-indol-3-yl)-alkyl] amines (illustrated below) as disclosed in PCT Publication No.


WO00/40580 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




dd. 1,4 disubstituted cyclohexane derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40579 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




ee. Arylpiperazinyl cyclohexyl derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40554 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




ff. Indol-3-yl-cyclohexylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51592 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




gg. N-aryloxyethyl-indoly-alkylamines (illustrated below) as disclosed in PCT Publication No. WO99/51591 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 hh. N-aryloxyethylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51576 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 ii. Aryloxyethyl-indoly-alkylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51575 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




jj. Substituted phenoxypropylamines (illustrated below) as disclosed in U.S. Patent Application No. 2002/0111358 and PCT Publication No. WO 02/422297 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




kk. Substituted aminothienopyridines (illustrated below) as disclosed in U.S. Patent No. 5,252,581 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




ll. Aromatic amines of arylpiperazines (illustrated below) as disclosed in PCT Publication No. WO 98/23590 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




mm. Piperidines and pyrrolidines (illustrated below) as disclosed in PCT Publication No. WO 97/40038 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



nn. The compound (+)-MCU-629 as shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 oo. Benzoxazinone derivatives (illustrated below) as disclosed in PCT Publication No. WO 03/091248 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5

pp. Indole derivatives (illustrated below) as disclosed in PCT Publication WO 01/46181 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

qq. The compound shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

rr. Tetrahydropyridine and piperazine derivatives (illustrated below) as disclosed in U.S. Patent Nos. 6,596,722, 6,476,035, and 6,391,882, U.S. Patent Application Nos. 2002/0035113, 2002/0173512, and 2003/0018050, and PCT Publication Nos. WO 00/43382, WO 99/05140, and WO 99/67237 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof; and



20

ss. The compound LU-36-274 as shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof.



5 2. The method of claim 1, wherein the sexual dysfunction is Premature Ejaculation.

10 3. The method of claim 1, wherein the active agent is administered from about 0 minutes to about 10 hours prior to commencement of an activity wherein suppression of the symptoms of sexual dysfunction would be desirable.

15 4. The method of claim 3, wherein the active agent is administered from about 0 minutes to about 6 hours prior to commencement of an activity wherein suppression of the symptoms of sexual dysfunction would be desirable.

20 5. The method of claim 3, wherein the active agent is administered from about 0 minutes to about 4 hours prior to commencement of an activity wherein suppression of the symptoms of sexual dysfunction would be desirable.

25 6. The method of claim 1, wherein the active agent is contained within a pharmaceutical formulation.

30 7. The method of claim 6, wherein the pharmaceutical formulation is a unit dosage form.

35 8. The method of claim 6, wherein the pharmaceutical formulation is a controlled release dosage form.

30 9. The method of claim 6, wherein the pharmaceutical formulation is a delayed release dosage form.

35 10. The method of claim 1, wherein the active agent is administered by a mode selected from the group consisting of oral, transmucosal, topical, transdermal, and parenteral.

5 11. The method of claim 10, wherein the active agent is administered transmucosally.

12. The method of claim 11, wherein the mode of transmucosal delivery of the active agent is selected from the group consisting of sublingual, buccal, intranasal, 10 transurethral, rectal, and inhalation.

13. The method of claim 10, wherein the active agent is administered orally.

14. The method of claim 6, wherein the active agent is administered orally.

15 15 The method of claim 14, wherein the pharmaceutical formulation is selected from the group consisting of tablets, capsules, caplets, solutions, suspensions, syrups, granules, beads, powders, pellets, and rapidly disintegrating tablets.

20 16. The method of claim 15, wherein the rapidly disintegrating tablet is an effervescent tablet.






17. The method of claim 15, wherein the pharmaceutical formulation comprises a tablet.


25 18. The method of claim 15, wherein the pharmaceutical formulation comprises a capsule.

19 19 The method of claim 6, wherein the pharmaceutical formulation further 30 comprises an additional active agent.


20. The method of claim 1, wherein the active agent is a compound selected from the group consisting of:

5






21. The method of claim 1, wherein the active agent comprises the following compound



10

22. A pharmaceutical formulation for treating sexual dysfunction, which comprises administering to an individual in need thereof a therapeutically effective amount of an active agent on an as-needed basis, wherein said active agent is selected from the group consisting of:

15 a. Substituted-benzyl or substituted-indolyl cyclic amino- substituted N-aryl or heteroaryl cyclic amines (illustrated below) as disclosed in U.S. Patent No. 6,225,324 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20

and/or hydrates thereof wherein

Z is selected from phenyl, benzodioxolone, benzodioxole, benzothiazole, pyridine, pyridazine, pyrimidine, and quinoline moieties that are

5


unsubstituted or optimally substituted with one to three substituents selected from C_{1-4} alkyl, C_{1-4} alkoxy, cyano, and halo; the solid and dotted lines denote either a double or a single covalent bond; m and n are independently integers 1 to 3; and



10


in which R_1 and R_2 are independently selected from hydrogen, halogen, and alkoxy, and R_3 is hydrogen, halogen, or cyano;

b. The compound shown below identified as BMS-296859;




15

c. Thiophene and benzothiophene compounds (illustrated below) as disclosed in U.S. Patent No. 6,262,056 and PCT Publication No. WO99/02516 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



20




d. 3-[2-(1-(4'-piperonylpiperazinyl))indolyl]-carboxaldehydes (illustrated below) as disclosed in PCT Publication No. WO94/25454 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

10


e. 3-[4-(3-substituted phenyl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propanol derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *Pharmazie* 57: 515-8 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

15




f. 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *J Med Chem* 45: 4128-39 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

20




5

g. The compound shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

h. 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-2-yl)propane derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *Pharmazie* 57: 355-7 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

i. 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives (illustrated below) as disclosed in Martinez-Esparza J *et al.* (2001) *J Med Chem* 44: 418-28 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20

5 j. 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propane derivatives (illustrated below) as disclosed in Martinez J *et al.* (2001) *Eur J Med Chem* 36: 55-61 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



10


k. 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives (illustrated below) as disclosed in Oficialdegui AM *et al.* (2000) *Farmaco* 55: 345-53 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



15


l. The compound VN2222 (illustrated below) as identified and disclosed in Tordera RM *et al.* (2002) *Eur J Pharmacol* 442: 63-71 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

20




25


m. Arylpiperazinyl cyclohexyl derivatives (illustrated below) as disclosed in U.S. Patent No. 6,465,482 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




n. Aryl piperazinyl cyclohexyl derivatives (illustrated below) as disclosed in U.S. Patent No. 6,337,336 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



10 o. Arylpiperazinyl-cyclohexyl indole derivatives (illustrated below) as disclosed in U.S. Patent No. 6,313,126 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 p. 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]-amines (illustrated below) as disclosed in U.S. Patent No. 6,313,114 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5

q. N-arloxyethyl-alkylamines (illustrated below) as disclosed in U.S. Patent No. 6,291,683 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

r. Tetrahydroisoquinolinyl-indole derivatives (illustrated below) as disclosed in U.S. Patent No. 6,245,780 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

s. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,221,863 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




t. 1,4-disubstituted cyclohexane derivatives (illustrated below) as disclosed in U.S. Patent No. 6,200,994 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20


5 u. Indol-3-yl-cyclohexylamine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,162,803 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 v. N-aryloxyethyl-indolyl-alkylamines (illustrated below) as disclosed in U.S. Patent No. 6,150,533 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 w. Aryloxyethyl-indolyl-alkylamine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,121,307 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




x. N-aryloxyethylarginine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,110,956 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




y. Aryl-8-azabicyclo[3.2.1]octanes (illustrated below) as disclosed in PCT Publication No. WO02/96906 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 z. Azaindole derivatives (illustrated below) as disclosed in PCT Publication No. WO00/64898 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



15 aa. Dihydroisoquinolinyl-indole derivatives (illustrated below) as disclosed in PCT Publication No. WO00/64886 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20 bb. 3,4-dihydro-2H-benzo [1,4] oxazine derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40581 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




cc. 3,4-dihydro-2Hbenzo [1, 4] oxazinyl-methyl)-[3- (1H-indol-3-yl)-alkyl] amines (illustrated below) as disclosed in PCT Publication No.

WO00/40580 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

dd. 1,4 disubstituted cyclohexane derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40579 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15


ee. Arylpiperazinyl cyclohexyl derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40554 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5 ff. Indol-3-yl-cyclohexylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51592 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 gg. N-aryloxyethyl-indolyl-alkylamines (illustrated below) as disclosed in PCT Publication No. WO99/51591 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 hh. N-aryloxyethylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51576 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20 ii. Aryloxyethyl-indolyl-alkylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51575 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




jj. Substituted phenoxypropylamines (illustrated below) as disclosed in U.S. Patent Application No. 2002/0111358 and PCT Publication No. WO 02/422297 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




kk. Substituted aminothienopyridines (illustrated below) as disclosed in U.S. Patent No. 5,252,581 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



ll. Aromatic amines of arylpiperazines (illustrated below) as disclosed in PCT Publication No. WO 98/23590 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




mm. Piperidines and pyrrolidines (illustrated below) as disclosed in PCT Publication No. WO 97/40038 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

nn. The compound (+)-MCU-629 as shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

oo. Benzoxazinone derivatives (illustrated below) as disclosed in PCT Publication No. WO 03/091248 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5

pp. Indole derivatives (illustrated below) as disclosed in PCT Publication WO 01/46181 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

qq. The compound shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

rr. Tetrahydropyridine and piperazine derivatives (illustrated below) as disclosed in U.S. Patent Nos. 6,596,722, 6,476,035, and 6,391,882, U.S. Patent Application Nos. 2002/0035113, 2002/0173512, and 2003/0018050, and PCT Publication Nos. WO 00/43382, WO 99/05140, and WO 99/67237 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof; and



20

ss. The compound LU-36-274 as shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof.



5 23. The pharmaceutical formulation of claim 22, further comprising a carrier
suitable for transmucosal drug delivery buccally, sublingually, intranasally, rectally, or by
inhalation.

10 24. The pharmaceutical formulation of claim 22, wherein the sexual
dysfunction is Premature Ejaculation.

15 25. The pharmaceutical formulation of claim 23, comprising a solid dosage
form for application to the buccal mucosa, and wherein the carrier is suitable for buccal
drug delivery.

20 26. The pharmaceutical formulation of claim 25, wherein the carrier is a
hydrolyzable polymer.

25 27. The pharmaceutical formulation of claim 25, wherein the dosage form
further comprises an adhesive suitable for affixing the dosage form to the buccal mucosa.

30 28. The pharmaceutical formulation of claim 23, comprising a dosage form
for application to the sublingual mucosa, and wherein the carrier is suitable for sublingual
drug delivery.

35 29. The pharmaceutical formulation of claim 23, comprising a dosage form
for application to the rectal mucosa, and wherein the carrier is suitable for rectal drug
delivery.

30 30 The pharmaceutical formulation of claim 29, comprising a rectal
suppository.

35 31. The pharmaceutical formulation of claim 23, comprising a dosage form
suitable for inhalation.

5

32. The pharmaceutical formulation of claim 31, comprising a liquid.

33. The pharmaceutical formulation of claim 31, comprising a dry powder.




34. The pharmaceutical formulation of claim 31 comprising an aerosol




10 composition.

35. The pharmaceutical formulation of claim 23, wherein the pharmaceutical formulation further comprises an additional active agent.

15


36. The pharmaceutical formulation of claim 22, wherein the active agent is a compound selected from the group consisting of:





37. The pharmaceutical formulation of claim 36, further comprising a carrier
10 suitable for transmucosal drug delivery buccally, sublingually, intranasally, rectally, or by
inhalation.


38. The pharmaceutical formulation of claim 22, wherein the active agent comprises the following compound



39. The pharmaceutical formulation of claim 38, further comprising a carrier suitable for transmucosal drug delivery buccally, sublingually, intranasally, rectally, or by inhalation.

40. A packaged kit for use in the treatment of sexual dysfunction on an as-needed basis, comprising: a pharmaceutical formulation of an active agent; a container housing the pharmaceutical formulation during storage and prior to administration; and instructions for carrying out drug administration in a manner effective to treat sexual dysfunction; wherein said active agent is selected from the group consisting of:

10 a. Substituted-benzyl or substituted-indolyl cyclic amino- substituted N-aryl or heteroaryl cyclic amines (illustrated below) as disclosed in U.S. Patent No. 6,225,324 and salts, enantiomers, analogs, esters, amides, prodrugs, 15 active metabolites, and derivatives thereof;




and/or hydrates thereof wherein

Z is selected from phenyl, benzodioxolone, benzodioxole, benzothiazole,

20 pyridine, pyridazine, pyrimidine, and quinoline moieties that are unsubstituted or optimally substituted with one to three substituents selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, and halo;

the solid and dotted lines denote either a double or a single covalent bond;

m and n are independently integers 1 to 3; and




25

in which R₁ and R₂ are independently selected from hydrogen, halogen, and alkoxy, and R₃ is hydrogen, halogen, or cyano;



5

b. The compound shown below identified as BMS-296859;



10


c. Thiophene and benzothiophene compounds (illustrated below) as disclosed in U.S. Patent No. 6,262,056 and PCT Publication No. WO99/02516 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



15


d. 3-[2-(1-(4'-piperonylpiperazinyl))indolyl]-carboxaldehydes (illustrated below) as disclosed in PCT Publication No. WO94/25454 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

20




e. 3-[4-(3-substituted phenyl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propanol derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *Pharmazie* 57: 515-8 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

10



f. 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *J Med Chem* 45: 4128-39 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;


15



g. The compound shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;


20

5




10

h. 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-2-yl)propane derivatives (illustrated below) as disclosed in Orus L *et al.* (2002) *Pharmazie* 57: 355-7 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



15


i. 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives (illustrated below) as disclosed in Martinez-Esparza J *et al.* (2001) *J Med Chem* 44: 418-28 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



20


j. 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propane derivatives (illustrated below) as disclosed in Martinez J *et al.* (2001) *Eur J Med Chem* 36: 55-61 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;

5




10

k. 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives (illustrated below) as disclosed in Oficialdegui AM *et al.* (2000) *Farmaco* 55: 345-53 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

l. The compound VN2222 (illustrated below) as identified and disclosed in Tordera RM *et al.* (2002) *Eur J Pharmacol* 442: 63-71 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20

m. Arylpiperazinyl cyclohexyl derivatives (illustrated below) as disclosed in U.S. Patent No. 6,465,482 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5


n. Aryl piperazinyl cyclohexyl derivatives (illustrated below) as disclosed in U.S. Patent No. 6,337,336 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 o. Arylpiperazinyl-cyclohexyl indole derivatives (illustrated below) as disclosed in U.S. Patent No. 6,313,126 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 p. 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]-
amines (illustrated below) as disclosed in U.S. Patent No. 6,313,114 and
salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites,
and derivatives thereof:




q. N-arloxyethyl-alkylamines (illustrated below) as disclosed in U.S. Patent No. 6,291,683 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




r. Tetrahydroisoquinolinyl-indole derivatives (illustrated below) as disclosed in U.S. Patent No. 6,245,780 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 s. 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,221,863 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 t. 1,4-disubstituted cyclohexane derivatives (illustrated below) as disclosed in U.S. Patent No. 6,200,994 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20 u. Indol-3-yl-cyclohexylamine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,162,803 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




v. N-aryloxyethyl-indoly-alkylamines (illustrated below) as disclosed in U.S. Patent No. 6,150,533 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



10 w. Aryloxyethyl-indoly-alkylamine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,121,307 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




x. N-aryloxyethylarginine derivatives (illustrated below) as disclosed in U.S. Patent No. 6,110,956 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5

y. Aryl-8-azabicyclo[3.2.1]octanes (illustrated below) as disclosed in PCT Publication No. WO02/96906 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

z. Azaindole derivatives (illustrated below) as disclosed in PCT Publication No. WO00/64898 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

aa. Dihydroisoquinolinyl-indole derivatives (illustrated below) as disclosed in PCT Publication No. WO00/64886 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




20

bb. 3,4-dihydro-2H-benzo [1,4] oxazine derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40581 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




cc. 3,4-dihydro-2Hbenzo [1, 4] oxazinyl-methyl)- [3- (1H-indol-3-yl)-alkyl] amines (illustrated below) as disclosed in PCT Publication No.


WO00/40580 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




dd. 1,4 disubstituted cyclohexane derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40579 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




ee. Arylpiperazinyl cyclohexyl derivatives (illustrated below) as disclosed in PCT Publication No. WO00/40554 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




ff. Indol-3-yl-cyclohexylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51592 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




gg. N-aryloxyethyl-indoly-alkylamines (illustrated below) as disclosed in PCT Publication No. WO99/51591 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10 hh. N-aryloxyethylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51576 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 ii. Aryloxyethyl-indoly-alkylamine derivatives (illustrated below) as disclosed in PCT Publication No. WO99/51575 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




jj. Substituted phenoxypropylamines (illustrated below) as disclosed in U.S. Patent Application No. 2002/0111358 and PCT Publication No. WO 02/422297 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




kk. Substituted aminothienopyridines (illustrated below) as disclosed in U.S. Patent No. 5,252,581 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




ll. Aromatic amines of arylpiperazines (illustrated below) as disclosed in PCT Publication No. WO 98/23590 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




mm. Piperidines and pyrrolidines (illustrated below) as disclosed in PCT Publication No. WO 97/40038 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;



nn. The compound (+)-MCU-629 as shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15 oo. Benzoxazinone derivatives (illustrated below) as disclosed in PCT Publication No. WO 03/091248 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




5

pp. Indole derivatives (illustrated below) as disclosed in PCT Publication WO 01/46181 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




10

qq. The compound shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof;




15

rr. Tetrahydropyridine and piperazine derivatives (illustrated below) as disclosed in U.S. Patent Nos. 6,596,722, 6,476,035, and 6,391,882, U.S. Patent Application Nos. 2002/0035113, 2002/0173512, and 2003/0018050, and PCT Publication Nos. WO 00/43382, WO 99/05140, and WO 99/67237 and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof; and



20

ss. The compound LU-36-274 as shown below and salts, enantiomers, analogs, esters, amides, prodrugs, active metabolites, and derivatives thereof.







5


41. The packaged kit of claim 40, wherein the sexual dysfunction is Premature Ejaculation.

42. The packaged kit of claim 40, wherein the active agent is a compound selected from the group consisting of:


10



5



; and



43. The packaged kit of claim 40, wherein the active agent comprises the following compound

10

